Neumann Advisory (HK)’s Sinovac Biotech, Ltd SVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.04M | Hold |
315,586
| – | – | 0.57% | 5 |
|
|
2026
Q1 | $2.04M | Hold |
315,586
| – | – | 0.64% | 5 |
|
|
2025
Q4 | $2.04M | Hold |
315,586
| – | – | 0.54% | 6 |
|
|
2025
Q3 | $2.04M | Hold |
315,586
| – | – | 0.52% | 7 |
|
|
2025
Q2 | $2.04M | Hold |
315,586
| – | – | 0.73% | 7 |
|
|
2025
Q1 | $2.04M | Hold |
315,586
| – | – | 0.88% | 8 |
|
|
2024
Q4 | $2.04M | Hold |
315,586
| – | – | 0.6% | 8 |
|
|
2024
Q3 | $2.04M | Hold |
315,586
| – | – | 0.83% | 9 |
|
|
2024
Q2 | $2.04M | Hold |
315,586
| – | – | 0.97% | 10 |
|
|
2024
Q1 | $2.04M | Hold |
315,586
| – | – | 1% | 9 |
|
|
2023
Q4 | $2.04M | Hold |
315,586
| – | – | 0.78% | 10 |
|
|
2023
Q3 | $2.04M | Hold |
315,586
| – | – | 0.82% | 10 |
|
|
2023
Q2 | $2.04M | Hold |
315,586
| – | – | 0.78% | 10 |
|
|
2023
Q1 | $2.04M | Hold |
315,586
| – | – | 0.9% | 10 |
|
|
2022
Q4 | $2.04M | Hold |
315,586
| – | – | 1.26% | 10 |
|
|
2022
Q3 | $2.04M | Hold |
315,586
| – | – | 0.72% | 11 |
|
|
2022
Q2 | $2.04M | Hold |
315,586
| – | – | 0.67% | 10 |
|
|
2022
Q1 | $2.04M | Hold |
315,586
| – | – | 0.45% | 12 |
|
|
2021
Q4 | $2.04M | Hold |
315,586
| – | – | 0.35% | 12 |
|
|
2021
Q3 | $2.04M | Hold |
315,586
| – | – | 0.36% | 12 |
|
|
2021
Q2 | $2.04M | Hold |
315,586
| – | – | 0.33% | 13 |
|
|
2021
Q1 | $2.04M | Hold |
315,586
| – | – | 0.36% | 11 |
|
|
2020
Q4 | $2.04M | Hold |
315,586
| – | – | 0.39% | 10 |
|
|
2020
Q3 | $2.04M | Hold |
315,586
| – | – | 0.52% | 10 |
|
|
2020
Q2 | $2.04M | Hold |
315,586
| – | – | 0.68% | 8 |
|
|
2020
Q1 | $2.04M | Hold |
315,586
| – | – | 1.09% | 9 |
|
|
2019
Q4 | $2.04M | Hold |
315,586
| – | – | 1.03% | 9 |
|
|
2019
Q3 | $2.04M | Hold |
315,586
| – | – | 1.19% | 9 |
|
|
2019
Q2 | $2.04M | Hold |
315,586
| – | – | 1.13% | 8 |
|
|
2019
Q1 | $2.04M | Hold |
315,586
| – | – | 1.09% | 9 |
|
|
2018
Q4 | $2.19M | Sell |
315,586
-58,922
| -16% | -$430K | 1.52% | 9 |
|
|
2018
Q3 | $2.85M | Sell |
374,508
-28,336
| -7% | -$204K | 1.68% | 9 |
|
|
2018
Q2 | $3M | Hold |
402,844
| – | – | 1.62% | 8 |
|
|
2018
Q1 | $3.47M | Hold |
402,844
| – | – | 2.03% | 8 |
|
|
2017
Q4 | $3.17M | Buy |
+402,844
| New | +$3.01M | 2.11% | 7 |
|
Neumann Advisory (HK)'s SVA Position: Q2 2026 in Review
Neumann Advisory (HK) held its Sinovac Biotech, Ltd (SVA) position steady in Q2 2026 at 315,586 shares worth $2.04M. The position accounts for 0.57% of the portfolio, ranked #5.
Neumann Advisory (HK) first reported a position in SVA in Q4 2017 and has held it in 35 quarters since. The position peaked at $3.47M in Q1 2018. 2 funds tracked by Wall St. Rank hold SVA as of Q2 2026.
- Neumann Advisory (HK) held 315,586 shares of Sinovac Biotech, Ltd worth $2.04M as of Q2 2026.
- Neumann Advisory (HK) left its Sinovac Biotech, Ltd share count unchanged in Q2 2026.
- Sinovac Biotech, Ltd made up 0.57% of Neumann Advisory (HK)'s portfolio in Q2 2026, its #5 holding.
- Neumann Advisory (HK) first reported a position in Sinovac Biotech, Ltd in Q4 2017 and has held it in 35 quarters since.
- Neumann Advisory (HK)'s Sinovac Biotech, Ltd position peaked at $3.47M in Q1 2018.
- 2 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2026.
Based on Neumann Advisory (HK)'s 13F filing for Q2 2026, filed 8 Jul 2026.